Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
There has been conflicting evidence
2022-01-06

There has been conflicting evidence on the possible receptor mechanisms that mediate the neuro-immuno-modulatory effects of FAAH substrates. Evidence from in vitro studies indicates that AEA-mediated modulation of TLR4-induced neuroinflammation may be mediated by CB1/CB2 receptor dependent (Correa e
-
Recent advances in imaging single protein mobility and
2022-01-06

Recent advances in imaging single protein mobility and organization in live organisms such as Drosophila larva motor nerve terminals have initiated this by providing a useful platform to investigate how the dynamic changes in the actomyosin network correlates with vesicle docking and fusion in vivo2
-
Syt itself does not catalyze
2022-01-06

Syt1 itself does not catalyze lipid mixing and membrane fusion. Rather, the pairing of vesicular and target membrane SNAREs into complexes serves to pull bilayers together to drive fusion; Ca•syt1 accelerates these fusion reactions so that they occur on rapid timescales in a manner that is precisel
-
In humans mutations in KDM A KDM B and
2022-01-06

In humans, mutations in KDM5A, KDM5B, and KDM5C are found in patients with ID, implicating KDM5-regulated transcription in the development or activity of neuronal tissues (Vallianatos and Iwase, 2015). KDM5D is Y-linked, and its role in cognition remains uncharacterized. Mutations in KDM5C are the m
-
Considering its role in regulating cytoskeletal dynamics
2022-01-05

Considering its role in regulating cytoskeletal dynamics, the Rho kinase effector ROCK has been particularly implicated in tumor metastasis. The ROCK inhibitors Y27632 and fasudil have been extensively studied in cancer and beneficial effects have been observed in many types of cancers (Kale et al.,
-
More recently several groups have
2022-01-05

More recently, several groups have characterized a role for GPR120 signaling via omega-3 fatty acids in amelioration of alcoholic hepatic injury and non-alcoholic fatty liver disease (NAFLD) [18], [19]. Nakamoto et al. demonstrated protective effects of the omega-3 fatty Cyanine 5-dCTP mg docosahex
-
In conclusion atorvastatin but not pravastatin impaired gluc
2022-01-05

In conclusion, atorvastatin but not pravastatin impaired glucose utilization in C2C12 cells and glucose tolerance in HFD mice, which may be partly due to the inhibition of GLUT4 translocation in muscle cells. The decrease in the cholesterol level induced by atorvastatin may partly account for the in
-
The effect of GCK NES
2022-01-05

The effect of GCK-NES mutations on enzyme kinetics and protein stability might account for the hyperglycaemia that characterizes MODY2 patients, since reduced GCK activity would increase the threshold for glucose stimulated insulin release in beta-cells [31,37,49]. However, a more in depth functiona
-
In this work we constructed a versatile platform based on
2022-01-05

In this work, we constructed a versatile platform based on MoS2-loaded molecular beacon(MB) and HCR for miRNA detection with high sensitivity and low-background. In this method, the G-quadruplex/Thioflavin T (THT) as fluorescent signal output, which possesses a variety of advantages, such as label-f
-
acetylcholine receptors All of the abovementioned effects of
2022-01-05

All of the abovementioned effects of PUFAs signal their involvement in a cellular phenotype switching phenomenon, which is increasingly recognized as a potential target for future pharmacotherapies of atherosclerosis, especially for individuals who do not respond to the classical lipid-lowering stra
-
The ETB receptor has been
2022-01-05

The ETB receptor has been shown to decrease sodium transport in the renal medullary collecting duct and medullary thick ascending limb of Henle10, 11, 12, 13, 18. However, both inhibitory and stimulatory effects of endothelin have been reported in the proximal tubule16, 47, 48, 49. In the rat, endot
-
PD153035 hydrochloride Antigen presentation of incoming vira
2022-01-05

Antigen presentation of incoming viral particles has been well studied for diverse viruses in antigen-presenting cells (APCs), mostly in dendritic cells and macrophages in the context of the exogenous antigens’ pathway to prime the CD8+ T cells. However, CD4+ T cells are not known as efficient APCs,
-
GSK is inhibited by serine phosphorylation at
2022-01-04

GSK-3 is inhibited by serine OR-486 at a residue its N-terminus (Ser 9 in GSK-3β and Ser 21 in GSK-3α) [52], [53], [54]. This raised the possibility that the N-terminal tail may function as a pseudo-substrate by mimicking the pre-phosphorylated substrate. The interaction mode of the pseudo-substrate
-
To date no studies have demonstrated any effect of
2022-01-04

To date, no studies have demonstrated any effect of obesity or inflammation on GPR109A expression in adipose tissue. Our findings demonstrate that HFD-induced obesity decreases adipose tissue GPR109A gene expression. Contradictory to our findings in adipose tissue in vivo, Digby et al. report that e
-
Several studies have proposed that high levels of KYNA
2022-01-04

Several studies have proposed that high levels of KYNA in the 4 68 receptor contribute to cognitive dysfunctions presented by patients who suffer from schizophrenia [30], [31], [32], [33]. Considering that: (i) KYNA is a known GPR35 agonist [2], (ii) cognitive impairments in patients with schizophr
15879 records 530/1059 page Previous Next First page 上5页 526527528529530 下5页 Last page